Elekta and RTsafe sign agreement to distribute personalized stereotactic quality assurance solutions
Stockholm, April 19, 2018
Elekta (EKTA-B.ST) announced today that it has signed a memorandum of understanding with RTsafe to distribute innovative, 3D printed pseudo in-vivo phantoms and remote dosimetry services. The agreement with RTsafe will provide cancer centers an elegant quality assurance (QA) solution by elevating confidence in the end-to-end accuracy of stereotactic systems and create wider access to advanced stereotactic treatments for millions of patients.
“Worldwide demand for stereotactic treatments are increasing, especially among the 20 to 40 percent of cancer patients who will develop brain metastases. That could be as many as four million individuals needing stereotactic radiosurgery (SRS) per year globally. This collaboration aligns well with Elekta’s ongoing mission to simplify the delivery of very complex therapeutic treatment techniques through our leading flagship system Versa HD™ with High definition dynamic radiosurgery (HDRS).” said Maurits Wolleswinkel, Head of Portfolio and Chief Strategy Officer at Elekta.
RTsafe and Elekta recently coordinated a six-center consortium to measure end-to-end accuracy of Elekta’s Versa HD High definition radiosurgery solutions. To view the webinar, click here.